295 results
8-K
EX-99.1
INFIQ
Infinity Pharmaceuticals, Inc.
25 Jul 23
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan
4:30pm
evaluation of its appeal request to Nasdaq; the potential, safety, efficacy, and regulatory and clinical progress of eganelisib, including
DEFA14A
INFIQ
Infinity Pharmaceuticals, Inc.
10 Jul 23
Additional proxy soliciting materials
8:30am
and subject to the successful close of the company’s proposed merger with MEI Pharma, Inc. (“MEI”), preliminary safety and efficacy data to inform the dose … survival and safety.
“Our ability to optimize the eganelisib dose in MARIO-8 is a very attractive component of this study, furthering our objective
DEFA14A
INFIQ
Infinity Pharmaceuticals, Inc.
5 Jul 23
Additional proxy soliciting materials
8:30am
runway; the competitive ability and position of the combined company; the potential, safety, efficacy, and regulatory and clinical progress of the combined
425
INFIQ
Infinity Pharmaceuticals, Inc.
3 Jul 23
Business combination disclosure
4:57pm
cost savings and cash runway; the competitive ability and position of the combined company; the potential, safety, efficacy, and regulatory
8-K
koycz o81qoao1vxlh86
3 Jul 23
Other Events
4:55pm
DEFA14A
78dp3aw8nu6
20 Jun 23
Additional proxy soliciting materials
8:30am
425
EX-99.1
yc62 kl3a
20 Jun 23
Business combination disclosure
8:02am
425
3p0uspcdhui3m647i1
20 Jun 23
Business combination disclosure
8:02am
425
EX-99.2
hgnza873m1n
20 Jun 23
Business combination disclosure
8:02am
8-K
EX-99.1
hc9y elo69j
20 Jun 23
Overview and Update on Pending Merger to Advance Three Promising Clinical
8:00am
8-K
EX-99.2
atmap
20 Jun 23
Overview and Update on Pending Merger to Advance Three Promising Clinical
8:00am
8-K
7yxgh
20 Jun 23
Overview and Update on Pending Merger to Advance Three Promising Clinical
8:00am
DEFA14A
40cv7 2xoblgxw0xjuhr
16 Jun 23
Additional proxy soliciting materials
12:33pm
DEFA14A
s20rsq n8zgu
6 Jun 23
Additional proxy soliciting materials
4:43pm
DEFM14A
9aib2z c1prthqv5
6 Jun 23
Proxy related to merger
4:31pm
8-K
EX-99.1
l0n5b29sm01g4w 7wc
14 Nov 22
Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
7:12am